BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29787001)

  • 21. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.
    Deraco M; Kusamura S; Virzì S; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Iusco DR; Baratti D
    Gynecol Oncol; 2011 Aug; 122(2):215-20. PubMed ID: 21665254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Lopez-Ramirez F; Sittig M; Munoz-Zuluaga C; Nieroda C; Gushchin V; Diaz-Montes T
    Ann Surg Oncol; 2021 Aug; 28(8):4655-4666. PubMed ID: 33393042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
    Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
    JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
    Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
    Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?
    Gonzalez Bayon L; Steiner MA; Vasquez Jimenez W; Asencio JM; Alvarez de Sierra P; Atahualpa Arenas F; Rodriguez del Campo J; Garcia Sabrido JL
    Eur J Surg Oncol; 2013 Oct; 39(10):1109-15. PubMed ID: 23870278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer.
    Halkia E; Spiliotis J
    J BUON; 2015 May; 20 Suppl 1():S12-28. PubMed ID: 26051328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up.
    Fagotti A; Costantini B; Petrillo M; Vizzielli G; Fanfani F; Margariti PA; Turco LC; Piovano E; Scambia G
    Gynecol Oncol; 2012 Dec; 127(3):502-5. PubMed ID: 23022234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study.
    Manzanedo I; Pereira F; Serrano Á; Pérez-Viejo E; Martínez-Torres B; Carrión L; Calzas J
    Clin Transl Oncol; 2019 Oct; 21(10):1357-1363. PubMed ID: 30788835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study.
    Safra T; Grisaru D; Inbar M; Abu-Abeid S; Dayan D; Matceyevsky D; Weizman A; Klausner JM
    J Surg Oncol; 2014 Nov; 110(6):661-5. PubMed ID: 24962381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
    Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
    J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.
    Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P
    Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study.
    Petrillo M; Zucchetti M; Cianci S; Morosi L; Ronsini C; Colombo A; D'Incalci M; Scambia G; Fagotti A
    J Gynecol Oncol; 2019 Jul; 30(4):e59. PubMed ID: 31074245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperthermic intraperitoneal chemotherapy in the treatment of recurrent ovarian cancer: When, and for whom?
    Ayhan A; Akilli H; Abasiyanik MA; Taskiran C
    J Surg Oncol; 2023 Mar; 127(3):457-464. PubMed ID: 36264620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
    Kim SI; Kim JH; Lee S; Cho H; van Driel WJ; Sonke GS; Bristow RE; Park SY; Fotopoulou C; Lim MC
    Gynecol Oncol; 2022 Dec; 167(3):547-556. PubMed ID: 36273925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study.
    Ceresoli M; Verrengia A; Montori G; Busci L; Coccolini F; Ansaloni L; Frigerio L
    J Gynecol Oncol; 2018 May; 29(3):e53. PubMed ID: 29533028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
    Gadducci A; Cosio S; Lippolis PV
    Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer.
    Lei Z; Wang Y; Wang J; Wang K; Tian J; Zhao Y; Chen L; Wang J; Luo J; Jia M; Tang H; He Q; Liao Q; Yang X; Guan T; Wang L; Cui S;
    JAMA Netw Open; 2020 Aug; 3(8):e2013940. PubMed ID: 32840622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
    Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
    J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
    Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
    Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.